Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > REGULATORY
REGULATORY
- Japan Govt Promulgates Economic Security Law
May 19, 2022
- Cabometyx Likely to Escape CEA Scheme Unscathed with No Price Cut
May 19, 2022
- 4 Drugs Face Zero Premium Rule for Low Cost Disclosures: May Price Listing
May 19, 2022
- Impact of Annual Price Revisions on Pharma Industry Hard to Gauge Comprehensively: Govt
May 19, 2022
- Cabinet Adopts Ordinance for Emergency Approval, COVID Drugs Subject to New System
May 18, 2022
- 2022 Honebuto Outline Calls for “Planned Investment” Towards a New Capitalism
May 18, 2022
- Dupixent Faces Second Re-Pricing in August with 11.7% Cut
May 18, 2022
- Taiho’s GIST Med Pimitespib, Cabotegravir/Rilpivirine Combo Use Up for PAFSC Review on May 30
May 18, 2022
- MHLW Panels Again Find No Significant Concerns over Safety of COVID-19 Vaccines
May 17, 2022
- Janssen’s COVID-19 Vaccine Up for MHLW Panel Review on May 30
May 17, 2022
- MHLW Orders Label Revisions for Dexamethasone, Betamethasone to Warn of Phaeochromocytoma Crisis
May 16, 2022
- 5 New Probable Cases of Acute Pediatric Hepatitis Found in Japan
May 16, 2022
- Japan Clears Bill to Create Emergency Approval System, Enforcement Slated by Month-End
May 13, 2022
- Health Minister Vows Thorough Discussions on Drug Pricing, Mentions Policy Veterans’ Proposals
May 13, 2022
- MHLW Panel Clears Solasia’s PTCL Drug for Approval
May 13, 2022
- Japan Confirms 1st Cases of BA.4, BA.5 Omicron Subvariants
May 13, 2022
- Japan Enacts Economic Security Law; Supply Chain Clauses to Take Effect in 9 Months after Promulgation
May 12, 2022
- Side Effects after Drug Switches Up for MHLW Panel Review: Minister
May 11, 2022
- Xevudy’s Reduced Efficacy against BA.2 Cited in Updated COVID Guide
May 11, 2022
- PMDA Publishes 1st Example of GMP Shortfalls; Failure to Check Name of Raw Material Supplier
May 10, 2022
ページ
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…